"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 3 | 5 |
| 2000 | 5 | 2 | 7 |
| 2001 | 3 | 5 | 8 |
| 2002 | 2 | 1 | 3 |
| 2003 | 3 | 3 | 6 |
| 2004 | 4 | 6 | 10 |
| 2005 | 3 | 3 | 6 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 5 | 2 | 7 |
| 2009 | 3 | 3 | 6 |
| 2010 | 1 | 5 | 6 |
| 2011 | 5 | 1 | 6 |
| 2012 | 4 | 1 | 5 |
| 2013 | 4 | 5 | 9 |
| 2014 | 6 | 8 | 14 |
| 2015 | 7 | 5 | 12 |
| 2016 | 5 | 2 | 7 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 4 | 1 | 5 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855.
-
Identification of distinct stool metabolites in women with endometriosis for non-invasive diagnosis and potential for microbiota-based therapies. Med. 2025 Feb 14; 6(2):100517.
-
ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight. 2024 Oct 08; 9(19).
-
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Na?ve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol. 2025 Feb; 43(4):403-411.
-
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Nov; 25(7):601-611.
-
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol. 2024 Oct; 19(10):1438-1448.
-
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15; 391(7):585-597.
-
Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. Antiviral Res. 2024 07; 227:105920.
-
Biomarkers associated with pulmonary exacerbations in a randomized trial of nintedanib for radiation pneumonitis. Radiother Oncol. 2024 07; 196:110320.
-
Deficiency of the Deubiquitinase UCHL1 Attenuates Pulmonary Arterial Hypertension. Circulation. 2024 Jul 23; 150(4):302-316.